Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-09-19 00:00:00 ET · period of report 2024-09-17 · accession 0002001011-24-000084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-09-19 | 2024-09-17 | LGND | Espinoza Octavio | CFO | M - OptEx | $79.63 | +1,486 | 25.8K | +6% | +$118.3K |
| DM | 2024-09-19 | 2024-09-17 | LGND | Espinoza Octavio | CFO | M - OptEx | $0.00 | -1,486 | 466 | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-17 | M | A | 69 | $57.22 | 25,885 | D | — | — | |
| 2 | Common | Common Stock | 2024-09-17 | M | A | 1,417 | $80.72 | 25,816 | D | — | — | |
| 3 | Derivative | Employee Stock Option (right to buy) | 2024-09-17 | M | D | 69 | $0.00 | 7,240 | D | $57.22 · — to 2030-10-01 | 69 Common Stock | (F1) As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2024-09-17 | M | D | 1,417 | $0.00 | 466 | D | $80.72 · — to 2026-08-01 | 1,417 Common Stock | (F2) The stock option is fully vested and exercisable. |